Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.59 |
| ▸ | GBA1 | P04062 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926654 | 0.89 | MAPT (0.62) | EPHA2GSK3AGBA1ALDH1A1MAPK13 | |
| SCHEMBL9926640 | 0.89 | ALDH1A1 (0.71) | EPHA2GSK3AGBA1ALDH1A1MAPK13 | |
| SCHEMBL9926650 | 0.87 | MAPT (0.74) | EPHA2GSK3AGBA1ALDH1A1MAPK13 | |
| SCHEMBL17739944 | 0.84 | GBA1 (0.71) | EPHA2GSK3AGBA1ALDH1A1MAPT | |
| SCHEMBL9926736 | 0.83 | GBA1 (0.77) | GBA1ALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL15993443 | 0.82 | ALDH1A1 (0.80) | GBA1ALDH1A1MAPTPOLBTP53 | |
| SCHEMBL9926641 | 0.81 | GBA1 (0.73) | GBA1ALDH1A1MAPTPOLBL3MBTL1 | |
| SCHEMBL2464155 | 0.80 | GBA1 (0.58) | EPHA2GSK3AGBA1ALDH1A1MAPT | |
| SCHEMBL9926652 | 0.80 | L3MBTL1 (0.53) | EPHA2GSK3AALDH1A1MAPK13LIMK1 | |
| SCHEMBL7362761 | 0.79 | MAPT (0.61) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | claimed |
| EP-3366688-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3366688-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2022-02-09 | — | — | EP | disclosed |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3366688-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2012078855-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | EPHA2 4869/4885GSK3A 4001/4885GBA1 1/4885 |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | EPHA2 4869/4885GSK3A 4001/4885GBA1 1/4885 |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | GBA1, GAA, GBA3 | EPHA2 4869/4885GSK3A 4001/4885GBA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.